Tafalgie Therapeutics capitalizes on more than ten years of promising French scientific work.
Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein able to modulate the transmission of pain information to the brain.
Tafalgie Therapeutics has developed and identified other new drug candidates.
surgeries are performed each year.
Tafalgie Therapeutics gathers around its management team and founding partners, a Scientific Committee and a Supervisory Board
Chief Strategy Office
President of the
Chairman on the board
Tafalgie Therapeutics is a simplified joint-stock biotechnology company, Spin-off of the IBDM laboratory (AMU/CNRS).
The society is created in october 2020 by five founders having complementary and internationally recognized expertise in the fields of neurosciences, research, finances and industrial development.
Réalisé avec ❤️